Flemming Ørnskov

Flemming Ørnskov

Danish pharmaceutical executive (born 1958)

Flemming Ørnskov (born 24 January 1958) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma since October 2019.2

From Wikipedia’s article on Flemming Ørnskov (this version), CC BY-SA 4.0.

Born Jan 24, 1958.1

About

He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel. He previously worked for Bayer, Bausch & Lomb and Novartis.

He is also the non-executive chairman of Waters Corporation, a position he's been holding since 2017.

Ørnskov was educated at the Esbjerg Gymnasium. He received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University. Ørnskov is qualified as a doctor in Denmark and has experience as a practicing hospital physician.

Ørnskov led Galderma's IPO on the Zurich stock exchange on March 22, 2024, one of the biggest offerings in Europe in years and the biggest in Switzerland since 2017. He declares Galderma plans to use the proceeds to pay down debt and invest in its pipeline.

From Wikipedia’s article on Flemming Ørnskov, shared under CC BY-SA 4.0.2

Companies

  • Shire plcChief executive officer Apr 30, 2013 to Jan 20193

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3